BioCentury | Oct 20, 2014
Company News

Asterand Bioscience, ReproCell deal

...ReproCell acquired the induced pluripotent stem cell (iPSC) reagents and services business of Stemgent Inc. , now...
BioCentury | Aug 6, 2012
Company News

BioSeek, Stemgent deal

...Stemgent for $9 million in cash (see BioCentury, July 23). BioSeek plc (LSE:ATD), Royston, U.K. Stemgent Inc....
BioCentury | Jul 23, 2012
Company News

Asterand, Stemgent deal

...In June, Stemgent said it will acquire Asterand's non-BioSeek Tissue Based Solutions business for $9 million...
...Feb. 22, 2010; Oct. 31, 2011 & May 7, 2012). Asterand plc (LSE:ATD), Royston, U.K. Stemgent Inc....
BioCentury | May 26, 2011
Strategy

iPS cells: Five years later

...patient-specific samples," said Matthew Singer, manager of scientific development at iPS cell and reagent company Stemgent Inc....
...Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Stanford University, Stanford, Calif. StemCells Inc. (NASDAQ:STEM), Palo Alto, Calif. Stemgent Inc....
BioCentury | May 17, 2010
Company News

Miltenyi Biotec, Stemgent deal

...Miltenyi received exclusive rights to commercialize Stemgent's existing stem cell product portfolio outside the U.S. Stemgent...
...will join Stemgent's board. Financial terms were undisclosed. Miltenyi Biotec GmbH , Bergisch Gladbach, Germany Stemgent Inc....
BioCentury | Mar 8, 2010
Financial News

Ubiquigent completes venture financing

...therapy Date completed: 3/3/10 Type: Venture financing Raised: £3 million ($4.5 million) Investor: Stemgent Inc. Note: Stemgent...
BioCentury | Nov 16, 2009
Finance

Ebb & Flow

...cells for research or therapeutic use . In April, Fate and reagent and tool company Stemgent Inc....
BioCentury | May 11, 2009
Company News

Fate Therapeutics, Stemgent deal

...Fate and Stemgent established the Catalyst program to provide induced pluripotent stem (iPS) cell technology to...
...Fate's iPS technology with Stemgent's reagents and tools. Fate Therapeutics Inc. , La Jolla, Calif. Stemgent Inc....
BioCentury | May 19, 2008
Company News

Asterand board of directors update

...LSE:ATD), Royston, U.K. Business: Functional genomics, ADMET, Supply/Service Appointed: Ian Ratcliffe, president and CEO of Stemgent Inc. WIR...
Items per page:
1 - 9 of 9
BioCentury | Oct 20, 2014
Company News

Asterand Bioscience, ReproCell deal

...ReproCell acquired the induced pluripotent stem cell (iPSC) reagents and services business of Stemgent Inc. , now...
BioCentury | Aug 6, 2012
Company News

BioSeek, Stemgent deal

...Stemgent for $9 million in cash (see BioCentury, July 23). BioSeek plc (LSE:ATD), Royston, U.K. Stemgent Inc....
BioCentury | Jul 23, 2012
Company News

Asterand, Stemgent deal

...In June, Stemgent said it will acquire Asterand's non-BioSeek Tissue Based Solutions business for $9 million...
...Feb. 22, 2010; Oct. 31, 2011 & May 7, 2012). Asterand plc (LSE:ATD), Royston, U.K. Stemgent Inc....
BioCentury | May 26, 2011
Strategy

iPS cells: Five years later

...patient-specific samples," said Matthew Singer, manager of scientific development at iPS cell and reagent company Stemgent Inc....
...Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Stanford University, Stanford, Calif. StemCells Inc. (NASDAQ:STEM), Palo Alto, Calif. Stemgent Inc....
BioCentury | May 17, 2010
Company News

Miltenyi Biotec, Stemgent deal

...Miltenyi received exclusive rights to commercialize Stemgent's existing stem cell product portfolio outside the U.S. Stemgent...
...will join Stemgent's board. Financial terms were undisclosed. Miltenyi Biotec GmbH , Bergisch Gladbach, Germany Stemgent Inc....
BioCentury | Mar 8, 2010
Financial News

Ubiquigent completes venture financing

...therapy Date completed: 3/3/10 Type: Venture financing Raised: £3 million ($4.5 million) Investor: Stemgent Inc. Note: Stemgent...
BioCentury | Nov 16, 2009
Finance

Ebb & Flow

...cells for research or therapeutic use . In April, Fate and reagent and tool company Stemgent Inc....
BioCentury | May 11, 2009
Company News

Fate Therapeutics, Stemgent deal

...Fate and Stemgent established the Catalyst program to provide induced pluripotent stem (iPS) cell technology to...
...Fate's iPS technology with Stemgent's reagents and tools. Fate Therapeutics Inc. , La Jolla, Calif. Stemgent Inc....
BioCentury | May 19, 2008
Company News

Asterand board of directors update

...LSE:ATD), Royston, U.K. Business: Functional genomics, ADMET, Supply/Service Appointed: Ian Ratcliffe, president and CEO of Stemgent Inc. WIR...
Items per page:
1 - 9 of 9